NETosis and the IL-36/IL-36R Axis in Psoriasis Pathogenesis

Study Background and Research Question

Psoriasis is a chronic inflammatory skin disorder characterized by aberrant keratinocyte proliferation and intense immune cell infiltration, affecting over 60 million individuals worldwide. While the contribution of T cells and cytokines is well-established, the role of neutrophils and neutrophil extracellular traps (NETs) in disease exacerbation remains incompletely understood. NETosis, a process distinct from apoptosis or necrosis, involves the release of chromatin meshworks decorated with antimicrobial proteins and cytokines. These NETs are now recognized as both microbial defense mechanisms and amplifiers of local inflammation. The reference study (Zhang et al., 2024) investigates the upstream triggers of NET formation in psoriatic lesions and explores the feedback between NETosis and the IL-36/IL-36R signaling axis, aiming to clarify their contributions to disease progression and therapeutic targeting.

Key Innovation from the Reference Study

The principal innovation of this study lies in its systematic dissection of the triggers and modulators of NETosis in psoriasis, with a focus on the interplay between toll-like receptor (TLR) ligands, purinergic signaling (notably P2X7R activation by ATP), and the IL-36/IL-36R axis. The authors demonstrate that TLR3 ligands—especially polyinosinic-polycytidylic acid (Poly(I:C))—potently induce NET formation, and that this effect is further enhanced by ATP, a danger-associated molecular pattern engaging P2X7 receptors. Moreover, they show that NETs in psoriatic tissue are decorated with interleukin-1β (IL-1β), amplifying inflammatory signaling. Critically, genetic or pharmacological blockade of IL-36R or NETosis reduces cytokine production and mitigates psoriatic pathology, identifying the IL-36/NETosis axis as a targetable feedback loop in cutaneous inflammation (Zhang et al., 2024).

Methods and Experimental Design Insights

The study employed both in vitro and in vivo approaches to model psoriatic inflammation and NETosis. Key methodologies included:

• Induction of NETosis in isolated human and murine neutrophils using TLR ligands (Poly(I:C), LPS), with or without ATP co-stimulation.
• Immunofluorescence and confocal microscopy to visualize NET formation, using DNA, myeloperoxidase (MPO), and neutrophil elastase (NE) as markers.
• Use of IMQ (imiquimod)-induced mouse models to recapitulate psoriasiform skin pathology, including time-course analysis of neutrophil infiltration and NET deposition.
• Genetic ablation (Il1rl2-deficient mice) and pharmacological inhibition of IL-36R to interrogate the role of this pathway in NETosis and cytokine expression.
• Quantification of inflammatory cytokines and chemokines by ELISA and multiplex assays in tissue and cell culture supernatants.

Immunofluorescence detection relied on validated secondary antibody workflows, emphasizing the importance of high-specificity, fluorescently labeled secondary antibodies such as goat anti-mouse IgG conjugates.

Core Findings and Why They Matter

The study's main findings can be summarized as follows:

• TLR3 ligands robustly induce NETosis in neutrophils, with ATP acting as a strong potentiator via P2X7R. This synergy suggests that extracellular ATP in inflamed tissue can exacerbate NET formation in psoriasis.
• NETs in psoriatic lesions are decorated with IL-1β. This finding connects NETosis to amplification of inflammatory cytokine signaling in the skin.
• Activation of IL-36R enhances NET formation and inflammatory feedback. Conversely, blockade or genetic deletion of IL-36R reduces NETosis, dampens cytokine production, and delays psoriatic lesion development.
• Blocking NETosis reduces the expression of both inflammatory cytokines and chemokines. This supports the hypothesis that NETs are not merely byproducts but active drivers of psoriatic inflammation.

These results refine our understanding of psoriasis by establishing the IL-36/IL-36R-NETosis axis as a central inflammatory amplifier and therapeutic target (Zhang et al., 2024).

Comparison with Existing Internal Articles

While the reference study centers on inflammatory skin disease, internal articles such as "HyperFluor 488 Goat Anti-Mouse IgG: Advancing Immunodetection" and "Amplifying Detection: HyperFluor 488 Goat Anti-Mouse IgG in Translational Endothelial Research" focus on protocol optimization and detection sensitivity in neuroepigenetics and vascular biology, respectively. Both emphasize the value of high-performance, fluorescently labeled secondary antibodies for immunofluorescence and western blot detection, aligning with the reference paper's reliance on precise immunodetection to quantify NETs and inflammatory mediators. The internal articles expand on troubleshooting, workflow reproducibility, and cross-domain detection requirements, providing practical guidance that complements the mechanistic insights from the psoriasis study. Notably, while the reference study addresses pathogenesis and inflammation, the internal resources guide researchers in refining detection workflows—showcasing the translational value of robust secondary antibodies across diverse biomedical fields.

Limitations and Transferability

The study's main limitations include its reliance on murine models and ex vivo neutrophil assays, which may not fully capture the complexity of human psoriatic disease or the heterogeneity of patient responses. While the IMQ-induced mouse model recapitulates major features of plaque psoriasis, distinct immunological and structural differences exist between mouse and human skin. Furthermore, the specific contribution of NET-derived IL-1β and other cytokines to the maintenance versus initiation of psoriatic lesions remains to be clarified in future human studies. The transferability of NETosis-targeted interventions and IL-36R blockade to clinical practice will require careful assessment of safety, efficacy, and off-target effects.

Protocol Parameters

• NETosis induction: Poly(I:C) at 10 μg/mL; ATP at 2 mM as a co-stimulant for 3–4 hours in neutrophil cultures.
• Immunofluorescence detection: Fix cells with 4% paraformaldehyde for 15 min; block in 1% BSA; use primary antibodies against MPO or NE, followed by a fluorescently labeled secondary antibody (e.g., goat anti-mouse IgG conjugate) at 1:500 dilution.
• IMQ-induced mouse model: Apply 62.5 mg of 5% IMQ cream daily to shaved dorsal skin for 5–7 days to induce psoriasiform lesions.
• IL-36R blockade: Use Il1rl2 knockout mice or administer anti-IL-36R antibody at 10 mg/kg intraperitoneally every 2 days during IMQ treatment.

Researchers should optimize antibody concentrations and blocking conditions based on sample type and imaging requirements.

Research Support Resources

For precise immunofluorescence, flow cytometry, and western blot detection of mouse IgG primary antibodies—as required in NET quantification and cytokine visualization—researchers can consider the HyperFluor™ 488 Goat Anti-Mouse IgG (H+L) Antibody (SKU K1204) from APExBIO. This affinity-purified, fluorescently labeled secondary antibody offers high specificity for mouse immunoglobulins and is compatible with a broad range of immunoassays. Its robust signal amplification and low background properties make it suitable for studies targeting neutrophil extracellular traps and inflammatory mediators in both basic and translational research. For application and workflow enhancement strategies, see detailed guidance in related internal articles on immunofluorescence and endothelial biology protocols.